首页> 外文会议>Conference on medical applications of laser-generated beams of particles IV >Laser-driven particle acceleration for radiobiology and radiotherapy: where we are and where we are going
【24h】

Laser-driven particle acceleration for radiobiology and radiotherapy: where we are and where we are going

机译:用于辐射生物学和放射疗法的激光驱动颗粒加速:我们在哪里以及我们要去的地方

获取原文

摘要

Radiation therapy of tumors progresses continuously and so do devices, sharing a global market of about $ 4 billions, growing at an annual rate exceeding 5%. Most of the progress involves tumor targeting, multi-beam irradiation, reduction of damage on healthy tissues and critical organs, dose fractioning. This fast-evolving scenario is the moving benchmark for the progress of the laser-based accelerators towards clinical uses. As for electrons, both energy and dose requested by radiotherapy are available with plasma accelerators driven by lasers in the power range of tens of TW but several issues have still to be faced before getting a prototype device for clinical tests. They include capability of varying electron energy, stability of the process, reliability for medical users. On the other side hadron therapy, presently applied to a small fraction of cases but within an exponential growth, is a primary option for the future. With such a strong motivation, research on laser-based proton/ion acceleration has been supported in the last decade in order to get performances suitable to clinical standards. None of these performances has been achieved so far with laser techniques. In the meantime a rich crop of data have been obtained in radiobiological experiments performed with beams of particles produced with laser techniques. It is quite significant however that most of the experiments have been performed moving bio samples to laser labs, rather moving laser equipment to bio labs or clinical contexts. This give us the measure that laser community cannot so far provide practical devices usable by non-laser people.
机译:肿瘤的放射治疗持续进展,所以设备,共享大约4亿美元的全球市场,每年增长超过5%。大多数进展涉及肿瘤靶向,多光束辐照,减少健康组织和临界器官的损伤,剂量分馏。这种快速发展的方案是​​用于基于激光的加速器朝向临床用途的移动基准。至于电子,放射疗法所需的能量和剂量都可用等离子体加速器,该等离子体加速器通过激光器驱动的电力范围的电源范围,但在获得临床试验的原型装置之前仍有几个问题仍然面临。它们包括不同电子能量,工艺稳定性,医疗用户可靠性的能力。在另一边强子疗法,目前应用于少数病例但在指数增长中,是未来的主要选择。通过如此强大的动机,过去十年来支持基于激光的质子/离子加速的研究,以便获得适合于临床标准的性能。到目前为止,迄今为止,这些表演都没有实现激光技术。同时,已经在用激光技术产生的颗粒的梁进行的放射生物学实验中获得了丰富的数据作物。然而,这是非常重要的,即大多数实验已经进行了将生物样本移动到激光实验室,而是将激光设备移动到生物实验室或临床环境。这为我们提供了激光群落无法到目前为止的措施提供非激光人可用的实用装置。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号